Type 2 diabetes

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Retrieved on: 
Tuesday, March 5, 2024

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
  • There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology.
  • Today, Dexcom G7 is available for them with a prescription.
  • To learn more about Stelo and do a benefits check to see if you’re eligible to get started now with Dexcom G7, visit https://www.dexcom.com/en-us/stelo .

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Monday, March 4, 2024

Key highlights of Better Therapeutics’ participation at ATTD include:

Key Points: 
  • Key highlights of Better Therapeutics’ participation at ATTD include:
    The late-breaking abstract findings further validate the use of AspyreRx ™ as a safe and effective treatment for patients with type 2 diabetes (T2D).
  • Abstract Title: Randomized, Controlled Trial Of A Novel Digital Therapeutic In Patients With Type 2 Diabetes: BT-001 Pivotal Trial 180 Day Outcomes
    Abstracts will be published in the peer-reviewed Journal of Diabetes Technology & Therapeutics.
  • Additionally, Better Therapeutics will host a sponsored industry symposium on Saturday, March 09, 2024, at 8:30 a.m. local time (CET).
  • Attendees will have the opportunity to experience AspyreRx firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth.

Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss

Retrieved on: 
Thursday, February 29, 2024

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    These outcomes stand in stark contrast to other real-world results of GLP-1 weight loss treatments.
  • At one year follow-up, both groups achieved significant and sustained improvement in weight loss, with no differences between the groups.
  • In line with these new findings, Virta announced the expansion of its Sustainable Weight Loss solution, a comprehensive approach to weight loss that enables employers and payers to offer responsible and individualized use of GLP-1s.
  • Members can achieve clinical weight loss without the use of medications, or with medications in combination with Virta’s personalized nutrition therapy.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

Diabetes Research Study in Santa Clarita Evaluating a New Approach To Helping Patients

Retrieved on: 
Monday, February 26, 2024

A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • “For many people living with diabetes, controlling blood glucose levels is a difficult journey,” said Dr. Sina Tebi, Principal Investigator at Care Access - Santa Clarita.
  • The local setting provides residents of Santa Clarita and surrounding communities the option to participate in clinical studies close to home.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Diabetes Research Study Evaluating a New Approach To Helping Patients Now Offered in Warwick

Retrieved on: 
Monday, February 26, 2024

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • (Photo: Business Wire)
    The combination of diabetes and obesity significantly increases one’s risk of heart attacks, stroke, liver disease, kidney disease, and other serious health problems.
  • Care Access is a global clinical research company helping to accelerate the future of medicine.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

Retrieved on: 
Wednesday, February 21, 2024

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.

Key Points: 
  • The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.
  • These codes are issued by the World Health Organization (WHO) and are used to show payers why a particular service was medically necessary.
  • The inclusion of NAFLD under the ICD-10 K76.0 code facilitates standardized billing for its diagnosis.
  • "This positive development is testament to the growing awareness of liver health and the intensifying need for effective diagnostic solutions.

MemorialCare Medical Group and Greater Newport Physicians Nationally Recognized for Blood Pressure and Diabetes Management by American Heart Association

Retrieved on: 
Friday, March 8, 2024

These awards celebrate a commitment to controlling the blood sugar levels in patients with diabetes and accurate blood pressure measurements.

Key Points: 
  • These awards celebrate a commitment to controlling the blood sugar levels in patients with diabetes and accurate blood pressure measurements.
  • "We are honored to have been nationally recognized by the American Heart Association and American Medical Association," says Dr. David Kim, chief executive officer, MemorialCare Medical Foundation.
  • MemorialCare Medical Group and Greater Newport Physicians earned these awards by achieving an exceptional 70% or greater rate of adhering to cardiovascular-focused clinical measures and controlling high blood pressure throughout its adult patient population.
  • "The high level of care they provide daily shows MemorialCare Medical Group and Greater Newport Physician's commitment to providing quality care for our patients."

The BioCollective® Awarded Groundbreaking Probiotic Patent

Retrieved on: 
Thursday, March 7, 2024

DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.

Key Points: 
  • The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
  • The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
  • The US Patent and Trademark Office issued US Patent No.
  • The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.